Table 4. Correlation between ER-β and PR expressions and clinicopathologic characteristics.
| ER-β | PR | |||||
|---|---|---|---|---|---|---|
| (+) | (-) | P | (+) | (-) | P | |
| Age (years) | ||||||
| ≥50 | 16 | 22 | 0.706 | 16 | 22 | 0.107 |
| <50 | 52 | 62 | 32 | 82 | ||
| Tumor size (cm) | ||||||
| ≥5 | 48 | 58 | 0.837 | 38 | 68 | 0.086 |
| <5 | 20 | 26 | 10 | 36 | ||
| Laterality | ||||||
| Bilateral | 50 | 57 | 0.446 | 41 | 67 | 0.008 |
| UnilateraI | 18 | 27 | 7 | 37 | ||
| Peritoneal metastasis | ||||||
| No | 57 | 44 | <0.001 | 40 | 61 | 0.003 |
| Yes | 11 | 40 | 8 | 43 | ||
| Signet-ring cells | ||||||
| Positive | 26 | 46 | 0.042 | 21 | 51 | 0.544 |
| Negative | 42 | 38 | 27 | 53 | ||
| Ascites | ||||||
| No | 30 | 23 | 0.031 | 19 | 34 | 0.407 |
| Yes | 38 | 61 | 29 | 70 | ||
| Ovarian metastases | ||||||
| Synchronous | 41 | 52 | 0.839 | 28 | 65 | 0.624 |
| Metachronous | 27 | 32 | 20 | 39 | ||
| Serum CEA (ng/mL) | ||||||
| Normal | 58 | 61 | 0.059 | 38 | 81 | 0.859 |
| >5 | 10 | 23 | 10 | 23 | ||
| Serum CA19-9 (U/mL) | ||||||
| Normal | 43 | 53 | 0.986 | 31 | 65 | 0.805 |
| >39 | 25 | 31 | 17 | 39 | ||
| Serum CA125 (U/mL) | ||||||
| Normal | 27 | 25 | 0.199 | 14 | 38 | 0.373 |
| >35 | 41 | 59 | 34 | 66 | ||